Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H1 2018

  • ID: 4518498
  • Drug Pipelines
  • 116 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Amgen Inc
  • InflaRx NV
  • ISU ABXIS Co Ltd
  • Novartis AG
  • NovelMed Therapeutics Inc
  • MORE
Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H1 2018

Summary:

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) pipeline Target constitutes close to 32 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes. The latest report Complement C5 - Pipeline Review, H1 2018, outlays comprehensive information on the Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein is encoded by the C5 gene. Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex.

C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes.

C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 5, 1 and 17 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Report covers products from therapy areas Immunology, Hematological Disorders, Gastrointestinal, Ophthalmology, Infectious Disease, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Dermatology, Respiratory, Genetic Disorders and Other Diseases which include indications Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), Chronic Inflammation, Autoimmune Disorders, Myasthenia Gravis, Sepsis, Age Related Macular Degeneration, Choroidal Neovascularization, Dry (Atrophic) Macular Degeneration, Inflammation, Intermediate Uveitis, Lupus Nephritis, Posterior Uveitis, Septic Shock, Acute Lung Injury, Acute Renal Failure (ARF) (Acute Kidney Injury), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Atopic Keratoconjunctivitis, Bacterial Pneumonia, Bacterial Sepsis, Benign Mucous Membrane Pemphigoid (Oral Cicatricial Pemphigoid), Brain Injury, Bullous Pemphigoid, Cardiovascular Inflammation, Community Acquired Pneumonia, Duchenne Muscular Dystrophy, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Guillain-Barre Syndrome, Hidradenitis Suppurativa, Ischemia, Ischemia Reperfusion Injury, Juvenile Macular Degeneration (Stargardt Disease), Liver Transplant Rejection, Lung Injury, Multiple Organ Failure, Nephropathy, Neuromyelitis Optica (Devic’s Syndrome), Peritonitis, Polypoidal Choroidal Vasculopathy, Pulmonary Edema, Sicca Syndrome (Sjogren), Subarachnoid Hemorrhage, Typical Hemolytic Uremic Syndrome (Shiga-Toxin Associated Hemolytic Uremic Syndrome), Uveitis and Wet (Neovascular / Exudative) Macular Degeneration.

Furthermore, this report also reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)
  • The report reviews Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Akari Therapeutics Plc
  • Amgen Inc
  • InflaRx NV
  • ISU ABXIS Co Ltd
  • Novartis AG
  • NovelMed Therapeutics Inc
  • MORE
Introduction

Report Coverage

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Overview

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Companies Involved in Therapeutics Development

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

Chugai Pharmaceutical Co Ltd

InflaRx NV

ISU ABXIS Co Ltd

Novartis AG

NovelMed Therapeutics Inc

Noxxon Pharma AG

Ophthotech Corp

Ra Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Swedish Orphan Biovitrum AB

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Drug Profiles

AcPepA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avacincaptad pegol sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bikaciomab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cemdisiran - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coversin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coversin LA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eculizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Complement C3 and Complement C5 for Ischemia Reperfusion Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Complement C5 for Age Related Macular Degeneration - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mubodina - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NM-9405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXD-19 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXD-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXD-21 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Protein to Inhibit Complement C5 for Immunology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-101295 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-101348 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RA-101495 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ravulizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ravulizumab next generation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Proteins to Inhibit Complement C5 for Myasthenia Gravis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-3918 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RG-6107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOBI-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Coversin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Complement Component 5a for Chronic Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tesidolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Dormant Products

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Discontinued Products

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Product Development Milestones

Featured News & Press Releases

Mar 15, 2018: Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210 In Complement Inhibitor Treatment-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Mar 08, 2018: InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa

Feb 12, 2018: Ra Pharmaceuticals Announces Completion of Dosing in Phase 2 Program of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria

Feb 06, 2018: Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials

Jan 16, 2018: Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)

Jan 09, 2018: InflaRx Receives IND Acceptance To Proceed With A Phase IIb Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa

Jan 08, 2018: Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment

Dec 26, 2017: Soliris (Eculizumab) Receives Marketing Authorization in Japan for the Treatment of Patients with Generalized Myasthenia Gravis (gMG)

Dec 21, 2017: Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients

Dec 11, 2017: Results Of Phase 1b/2 Dose Regimen Optimization Studies For ALXN1210 In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Presented At American Society Of Hematology (ASH) Meeting

Dec 08, 2017: Akari Therapeutics Announces Phase II COBALT trial of Coversin in Patients with PNH Met the Primary Endpoint

Dec 04, 2017: Ra Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of RA101495 SC in Paroxysmal Nocturnal Hemoglobinuria

Nov 06, 2017: Alexion Receives New Japanese Patent for Soliris (eculizumab), Extending Patent Protection Into 2027 and Strengthening Global Patent Portfolio

Nov 01, 2017: New Phase 1/2 Study Data for ALXN1210 as a Potential Future Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Be Presented at American Society of Hematology (ASH) Meeting

Oct 23, 2017: FDA Approves Soliris (Eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Akari Therapeutics Plc, H1 2018

Pipeline by Alexion Pharmaceuticals Inc, H1 2018

Pipeline by Alnylam Pharmaceuticals Inc, H1 2018

Pipeline by Amgen Inc, H1 2018

Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Pipeline by InflaRx NV, H1 2018

Pipeline by ISU ABXIS Co Ltd, H1 2018

Pipeline by Novartis AG, H1 2018

Pipeline by NovelMed Therapeutics Inc, H1 2018

Pipeline by Noxxon Pharma AG, H1 2018

Pipeline by Ophthotech Corp, H1 2018

Pipeline by Ra Pharmaceuticals Inc, H1 2018

Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Pipeline by Swedish Orphan Biovitrum AB, H1 2018

Dormant Products, H1 2018

Dormant Products, H1 2018 (Contd..1), H1 2018

Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Akari Therapeutics Plc
  • Alexion Pharmaceuticals Inc
  • Alnylam Pharmaceuticals Inc
  • Amgen Inc
  • Chugai Pharmaceutical Co Ltd
  • InflaRx NV
  • ISU ABXIS Co Ltd
  • Novartis AG
  • NovelMed Therapeutics Inc
  • Noxxon Pharma AG
  • Ophthotech Corp
  • Ra Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc
  • Swedish Orphan Biovitrum AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll